genprowebdirectory
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Cancer
Poor Lung Cancer Response to Immunotherapy Linked to Commensal Bacteria, Suppressed…
Animal Models
How Well Do Mouse Models Mimic Human Disease?
GPCRs
IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics
Immunology
How Signaling Molecules of the Immune System Protect against Disease
Cancer
Changing Carcinogenic Cells in the Lungs with Novel Technology
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
Spatial Biology
Spatial Biology Current State of the Art and What’s Coming Next
Spatial Biology
GEN Interview with Joseph M. Beechem, PhD, Chief Scientific Officer of…
Spatial Biology
Choosing the Right Spatial Technology
Spatial Biology
Spatial and NGS Dominate Proceedings at AGBT 2022
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Home
Cancer
Head and Neck Cancer
Head and Neck Cancer
Anal Cancer
Bladder Cancer
Bone Marrow Cancer
Brain Cancer
Breast Cancer
Cancer Associated Pain
Cervical Cancer
Colorectal Cancer
Endometrial Cancer
Esophageal Cancer
Gastric Cancer
Head and Neck Cancer
Leukemia
Liver Cancer
Lung Cancer
Lymphoma
Mesothelioma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Sarcoma
Skin Cancer
Stomach Cancer
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Head and Neck Cancer
Somatic Cell Copy Number Changes in HNSC Cancer Predict Immunotherapy Response
Head and Neck Cancer
After Seven Patient Deaths, MacroGenics Halts Phase II Trial
Head and Neck Cancer
Samples from Failed Immunotherapy Trial Yield Genomic Clues to Safer Dosing
Head and Neck Cancer
Fighting Cancer with a Trojan Horse
Head and Neck Cancer
Malaria Drug Could Combat Head and Neck Cancer Chemotherapy Resistance
Head and Neck Cancer
Cancer’s Cartographer Redraws Tumor Treatment
Head and Neck Cancer
Turning Up the Heat on Cold Tumors
Head and Neck Cancer
Improving Cancer Immunotherapy by Inhibiting an Enzyme’s Activity
Head and Neck Cancer
Critical Recurring Mutation Identified in Head and Neck Cancers
Head and Neck Cancer
BioNTech Boosting Pipeline, Manufacturing, Global Presence with $325M in Series B...
Head and Neck Cancer
After Patient Dies, FDA Imposes Clinical Hold on Trial of Advaxis/AstraZeneca...
Head and Neck Cancer
Biofilms in Tonsil Crypts May Explain HPV-Related Head and Neck Cancers
Head and Neck Cancer
PDS, Merck Agree to Phase II Combo Study with Keytruda and...
Head and Neck Cancer
PD-L2 Helps Predict Immunotherapy Responsiveness for Head and Neck Cancer
Head and Neck Cancer
XOMA Licenses TGFb Immuno-Oncology Program to Novartis for Up to $517M+
1
2
3
4
Page 1 of 4
Scroll Up
Login
Subscribe